Safety and tolerability of adjuvant FOLFOX vs. CAPOX in colon cancer: A real-world experience.

e15689Background: Prospective clinical trials comparing FOLFOX to CAPOX are limited in the adjuvant setting and the only published trial was stopped early for poor accrual (Pectasides et al, 2015). We performed a retrospective analysis to investigate the tolerability of both regimens in patients with high-risk stage II or stage III colon cancer. Methods: Prospectively maintained pharmacy databases in our regional cancer group were interrogated for patients who were prescribed adjuvant FOLFOX (12 cycles) or CAPOX (8 cycles). Baseline patient characteristics were collected as well as treatment data including number of chemotherapy cycles administered, dose modifications or delays, hospitalizations and reported toxicities according to CTCAE v4. Disease free survival (DFS) and overall survival (OS) were recorded. Results: Between 2011 and 2017, 268 patients who received 5-flourouracil and/or oxaliplatin based regimens were identified; 96 of these were treated in the adjuvant setting for colon cancer and were ...